Scholars Central

Short communicationPublished 17 Dec 2020

A Short Note on Ledipasvir Sofosbuvir

Authors: Sharath Kumar

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Ledipasvir sold below the brand Harvoni among others, may be a medication accustomed treat viral hepatitis. It's a fixeddose combination of ledipasvir and sofosbuvir. Cure rates are ninety four to ninety nine in individuals infected with viral hepatitis virus (HCV) genotype one. Some proof additionally supports use in HCV genotype three and four. It’s taken daily orally for 8–24 weeks. It is usually well tolerated. Common aspect effects embrace muscle pains, headache, nausea, rash, and cough. It is unclear if use in physiological state is safe for the baby. Ledipasvir works by decreasing the activity of NS5A and sofosbuvir works by decreasing the activity of NS5B enzyme.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Liver: Disease & Transplantation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Liver: Disease & Transplantation
  • SubjectGastroenterology & Hepatology
  • SubjectSurgery
  • BylineArticles whose byline prints “Sharath Kumar”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels